주제: Cancer Precision Medicine Initiative
연사: 김열홍 교수 (고려대학교 의과대학 내과학교실)
일시: 2019년 3월 18일(월) 오후 5시
장소: 자연계캠퍼스 우정정보관 601호
주최: 고려대학교 BK21플러스 뇌공학SW인재양성사업단, 뇌인공지능연구센터, 뇌공학연구소
후원: 고려대학교 뇌공학과, 뇌인지과학융합전공, 인공지능 대학ICT연구센터
Precision medicine is an approach to patient care that allows doctors to select treatments that are most likely to help patients based on a genetic understanding of their disease. Cancer is a disease of the genome and as more is learned about cancer tumors, the more we are finding that each tumor has its own set of genetic changes. Understanding the genetic changes that are in cancer cells is leading to more effective treatment strategies that are tailored to the genetic profile of each patient’s cancer. Precision oncology or precision medicine of cancer focuses on matching the most accurate and effective treatment to each individual cancer patient based on the genetic profile of the cancer and the individual. Because every single cancer patient exhibits a different genetic profile and the profile can change over time, more patients will benefit if therapeutic options can be tailored to that individual, thus avoiding the idea that “one-size-fits-all” in terms of cancer treatment.
In 2017, Korean Precision Medicine Enterprise was launched. Korean Precision Medicine Enterprise are composed of Cancer Diagnosis & Treatment (K-MASTER) Enterprise and Precision-Hospital Information System (P-HIS) Enterprise. The research objective of K-MASTER Enterprise is developing a global precision medical cancer diagnosis and treatment method by establishing a comprehensive integration platform with the best possible integration of the molecular diagnosis and new targeted agents, which can be used in the near term. Also, K-MASTER aims to operate and expand the development of a large scale genomic and clinical data warehouse, combined with various solution developments for precision medicine of cancer patients.
The details of Korean Precision Medicine Enterprise project, which is an innovative initiative of Precision Medicine in Korea, will be discussed.